Brent Saunders will lead an expanded senior management team comprising leaders from both companies
The senior management team that will lead Actavis following the successful completion of the acquisition of Allergan has been announced.
Brent Saunders will continue to lead Actavis as CEO and President and a member of the Board of Directors, while Paul Bisaro will remain Executive Chairman.
Saunders will lead an expanded senior management team comprising leaders from both Actavis and Allergan.
Following the close of the acquisition in the second quarter of 2015, the company's global brand sales and marketing will be structured into three organisations: International Brands, Branded Pharma and Allergan Medical.
Paul Navarre, Allergan Corporate Vice President and President Europe, Africa and the Middle East, will become Executive Vice President Actavis, and President, International Brands.
William Meury, Actavis Executive Vice President for North American Brands will become Executive Vice President Actavis, and President, Branded Pharma with responsibility for Eye Care, Neurosciences, Gastroenterology, Urology, Women's Health and other Specialty brand portfolios.
Philippe Schaison, Allergan Corporate Vice President, President Allergan Medical, will become Executive Vice President Actavis, President Allergan Medical, which will include Facial Aesthetics, Medical Dermatology, Plastic Surgery and SkinMedica.
'Our combined company will have commercial operations in more than 100 countries, and a more complex combined portfolio of brand products,' said Saunders. 'With Paul, Bill and Philippe, we will have the strongest and most dynamic commercial leadership team in the industry, ensuring that we retain the intellectual firepower that has driven Allergan's commercial success, while retaining a laser-like focus on continuing to drive strong growth among our existing portfolio.'
With a commitment to invest more than US$1bn in brand product development, brand pharmaceutical R&D for the combined company at close will be led by Actavis' David Nicholson, Senior Vice President, Global Brand R&D in the role of Executive Vice President, Branded R&D.
To ensure the continued strength of its global generics business, Robert Stewart, currently Actavis' Chief Operating Officer, will become Executive Vice President Actavis, and President, Generics and Global Operations.
To support the larger and more complex company, the senior management team for its Global Functions, will include Maria Teresa (Tessa) Hilado, who will become EVP, Chief Financial Officer for the combined company and Robert Bailey will serve as EVP, Chief Legal Officer and Corporate Secretary.
Karen Ling, will become EVP, Chief Human Resources Officer; Charlie Mayr will serve as EVP, Chief Communications Officer; Sigurd Kirk will become EVP, Corporate Business Development and Jonathan Kellerman will become EVP and Global Chief Compliance Officer.
Finally, Alex Kelly, Actavis' Senior Vice President and Chief Integration Officer; and Sanjiv Patel, Allergan's Corporate Vice President, Global Strategic Marketing & Global Health Outcomes Strategy and Research, will jointly share in the responsibility for Pre-Integration Planning. Patel will also continue in his current role leading the Allergan's Global Strategic Marketing and Global Health Outcomes Research and Strategy organisation.